Physician profile
Alexia C Vaughn
NPI 1437182854
$3,740.89
in general payments reported to CMS, 2019-2025
17 companies · $474 in 2025
The $474 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,573 · 2020: $99.85 · 2021: $235 · 2022: $150 · 2023: $636 · 2024: $573 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,683.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,682.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,559.12 | 2019-2025 | Precision7, Precision 1 |
| Bausch & Lomb Americas INC. | $734.53 | 2022-2025 | Infuse, Zenlens, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $293.08 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $255.88 | 2024-2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $245.82 | 2023-2024 | Acuvue |
| Sun Pharmaceutical Industries INC. | $239.65 | 2019-2024 | |
| Lkc Technologies, INC. | $93.56 | 2023 | |
| Oyster Point Pharma, INC. | $85.17 | 2022-2024 | Tyrvaya |
| Harrow Eye, LLC | $49.63 | 2025 | Vevye |
| Novartis Pharmaceuticals Corporation | $42.77 | 2021-2022 | |
| Visioneering Technologies, INC. | $30.00 | 2019 | |
| Aerie Pharmaceuticals, INC. | $29.54 | 2020 | |
| Kala Pharmaceuticals, INC. | $24.35 | 2021 | |
| Carl Zeiss Meditec USA, INC. | $23.26 | 2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $15.13 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexia Vaughn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.